Clicky

Dimerix Ltd  (DXB)

Description: Dimerix Bioscience Ltd, formerly Dimerix Bioscience Pty Ltd, is engaged in developing and commercializing drug therapies and drug discovery tools. The Company’s business activity focuses on the clinical development of the Company’s therapeutic product (DMX200), which is targeted at treatind patients with chronic kidney disease; the development of other therapeutic oppurtunities generated from the use of its cell-based drug discovery assay technology (know as Receptor-HIT), and growing its assay business through the use of Receptor-HIT to assist third parties in their own drug discovery and development processes through contract research. DMX200 is a therapeutic approach to treating chronic kidney disease. It comprises two drugs: irbesartan and propagermanium.


Keywords: Life Sciences Disease Drugs Health Sciences Drug Discovery Chronic Kidney Disease Drug Therapies Organ Failure Angiotensin Ii Receptor Blocker

Home Page: dimerix.com

DXB Technical Analysis

425 Smith Street
Fitzroy, VIC 3065
Australia
Phone: 1300 813 321


Officers

Name Title
Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D. CEO, MD & Director
Dr. Ashish Soman M.B.A., M.D., MBBS Chief Medical Officer
Mr. Hamish George B.Com., C.A. CFO & Company Sec.
Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D. Chief Scientific Advisor
Ms. Elizabeth McCall B.Com(Hons), B.Juris, BJURIS, GAICD, L.L.B., LLB. Bus. Devel. Officer

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.6709
Price-to-Sales TTM: 8.1883
IPO Date:
Fiscal Year End: June
Full Time Employees: 0
Back to stocks